statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	592
CN - Cina	188
SG - Singapore	167
DE - Germania	151
GB - Regno Unito	145
IT - Italia	100
VN - Vietnam	65
HK - Hong Kong	61
SE - Svezia	60
RU - Federazione Russa	43
BD - Bangladesh	41
BR - Brasile	37
CA - Canada	28
IN - India	28
TR - Turchia	27
FR - Francia	23
NL - Olanda	19
IE - Irlanda	17
FI - Finlandia	16
DK - Danimarca	13
CI - Costa d'Avorio	12
ID - Indonesia	7
AR - Argentina	6
JP - Giappone	6
CH - Svizzera	5
KR - Corea	5
UA - Ucraina	5
ZA - Sudafrica	5
PL - Polonia	4
BE - Belgio	3
EC - Ecuador	3
IQ - Iraq	3
SA - Arabia Saudita	3
TW - Taiwan	3
UZ - Uzbekistan	3
AT - Austria	2
DZ - Algeria	2
GR - Grecia	2
MA - Marocco	2
PY - Paraguay	2
RO - Romania	2
AE - Emirati Arabi Uniti	1
AU - Australia	1
AZ - Azerbaigian	1
BG - Bulgaria	1
CL - Cile	1
CO - Colombia	1
CY - Cipro	1
HN - Honduras	1
IR - Iran	1
JM - Giamaica	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LB - Libano	1
LK - Sri Lanka	1
MD - Moldavia	1
MY - Malesia	1
NZ - Nuova Zelanda	1
OM - Oman	1
PA - Panama	1
PE - Perù	1
PH - Filippine	1
PT - Portogallo	1
SC - Seychelles	1
SI - Slovenia	1
SV - El Salvador	1
TJ - Tagikistan	1
TN - Tunisia	1
VE - Venezuela	1
Totale	1.934

Nome	#
At the peak of Covid-19 age and disease severity but not comorbidities are predictors of mortality. Covid-19 burden in Bergamo, Italy	331
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort	301
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C	229
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study	214
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting	200
Renal safety in 3264 HCV patients treated with DAA-based regimens : results from a large Italian real-life study	185
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure	175
AISF position paper on HCV in immunocompromised patients	152
Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination.	105
Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients	91
Hepatitis B Immunoglobulins Withdrawal in Hepatitis B Virus Mono-Infected Liver Transplant Recipients: An Italian Multicentre Prospective Study	9
Totale	1.992

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	27	0	0	0	0	0	0	0	0	0	0	13	14
2021/2022	210	15	11	14	13	10	6	25	37	29	18	8	24
2022/2023	203	28	34	19	22	21	32	0	8	18	1	19	1
2023/2024	181	3	10	11	15	47	18	12	17	6	7	18	17
2024/2025	356	16	32	15	39	25	10	19	22	16	37	41	84
2025/2026	776	83	63	100	55	72	40	121	16	55	59	112	0
Totale													1.992

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca